GNMX Description — Aevi Genomic Medicine Inc
Aevi Genomic Medicine is a clinical stage biopharmaceutical company with a focus on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated therapies for pediatric onset, life-altering diseases, including rare and orphan diseases. Co.'s product pipeline includes: AEVI-002, which is an anti-LIGHT monoclonal antibody that is in development for use in Pediatric Onset Crohn's disease; and AEVI-005, which is the monoclonal antibody Co. is developing as part of its ongoing collaboration with Kyowa Hakko Kirin Co., Ltd. whereby Co. is studying it in an undisclosed ultra-orphan auto-immune pediatric disease.